Most Read Articles
6 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
5 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

2 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.

Intraperitoneal paclitaxel-cisplatin therapy does not prolong survival in stage III ovarian cancer

22 Oct 2020

Intraperitoneal therapy with paclitaxel and cisplatin does not result in longer progression-free or overall survival in the adjuvant setting among patients with stage III ovarian cancer as compared with dose-dense paclitaxel and carboplatin, results of a study have shown. In addition, tolerability appears to have decreased with intraperitoneal therapy.

The investigators conducted a retrospective, single-centre chart review to compare progression-free survival, overall survival, and tolerability of adjuvant intraperitoneal paclitaxel and cisplatin to dose-dense paclitaxel and carboplatin in stage III ovarian cancer. Adult patients undergoing adjuvant intraperitoneal therapy or dose-dense therapy between 2010 and 2018 were included.

Of the 82 patients included in the final analysis, 44 received intraperitoneal therapy and 38 dose-dense therapy. The former did not substantially prolong progression-free survival when compared with the latter (35.4 vs 31.1 months; p=0.97). Overall survival duration also did not differ between intraperitoneal and dose-dense therapy (56.3 vs 54.5 months; p=0.55).

Patients on intraperitoneal therapy had less frequent dose reductions than those on dose-dense therapy (11.36 percent vs 31.58 percent; p=0.002).

Furthermore, no between-group difference was seen in treatment delays (45.5 percent vs 65.8 percent; p=0.07), dose cancellations (59.1 percent vs 57.9 percent; p=0.91), supportive care additions (95.5 percent vs 84.2 percent; p=0.09), or therapy discontinuation (59.1 percent vs 39.5 percent; p=0.07).

“Patients diagnosed with stage III ovarian cancer are at high risk of recurrence, and optimal adjuvant therapy is often debated,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
5 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

2 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.